DermTech, Inc. has announced two new collaborations with pharmaceutical companies and expects more to follow as the demand for personalized, precision medicine increases.
LiveLeaf, Inc. has announced a collaboration with the contract research organization (CRO), Emery Pharma, to advance its development of novel prodrugs for FDA approval.
BioCelerate has partnered with Accenture to develop a platform that will aggregate and analyze preclinical and clinical information to "drive additional industry value."
Diteba has developed a novel in vitro approach that allows sponsors to avoid in vivo bioequivalence studies in accordance with a recently released FDA draft guidance.
Charles River Laboratories has launched a triple-immunodeficient mouse model – a humanized mouse model, the likes of which are “the future of oncology research,” says CRO.
Butterworth Laboratories Ltd has secured an additional facility in Hampton, Middlesex as it aims to increase capacity by 60% over the next three years.
WuXi AppTec’s LabNetwork is collaborating with Reaxys in order to simplify customer’s purchasing decisions and expand exposure to the WuXi eCommerce platform.
The expanded facility features an additional 4,200 square feet of space to enhance its microbiology, sterility testing, and microbial ID service offerings.
Envigo is developing new In vitro tests in advance of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) recommendations expected at the end of the year.
The US Justice Department has announced Charles River Laboratories International Inc. will pay the US government $1.8m to settle claims that it violated the False Claims Act.
Heptares Therapeutics has entered into a drug discovery and licensing agreement with Daiichi Sankyo – providing further validation of the company’s structure-based drug design approach, says CEO.
Cytel Inc. has established a dedicated quantitative pharmacology and pharmacometrics team to meet an increasing demand for model-informed drug development from biopharma clients.
Charles River Laboratories has extended its integrated respiratory program with Chiesi Farmaceutici, through which it identifies and tests candidates for preclinical development.
SRI International will advance compounds with the potential to treat persons exposed to biological, radiation, nuclear, and chemical agents – in a deal worth up to $90m.
Certara has developed a new licensing approach, which provides smaller organizations access to its physiologically-based pharmacokinetic (PBPK) modeling and simulation platform.
NovAliX has signed an insourcing agreement with UCB Biopharma, a model that the CRO says “energizes scientific organization” and offers "significant" cost advantages.
Cerveau has signed a research agreement through which it will supply its early-stage imaging agent to assess the stages of Alzheimer’s disease and other neurodegenerative diseases.
Irish Luxcel will grant access to its consumable in vitro cell toxicity tests to Shanghai-based CRO HD Biosciences to help reduce the risk of post-market drug withdrawal.
Genesis Biotechnology Group (GBG) has acquired the preclinical CRO PharmOptima in order to provide customers with a single point-of-contact throughout their drug development programs.
The Global Biological Standards Institute (GBSI) has outlined an action plan after finding the frequency of irreproducible preclinical research exceeds 50% – costing the US nearly $28bn.
Dubbed LAB282, the £13m (€15M) Oxford University drug discovery program with Evotec has announced two grant winners and a second set of awards of up to £250,000.
Almac Discovery and the Royal College of Surgeons in Ireland (RCSI) and have announced a research collaboration aimed at understanding how to target therapy-resistant cancer tumors.
Researchers need to design more translationally relevant animal studies to improve the potential for success in human clinical trials, according a recent report.
AMRI has entered an alliance through which the global contract research and manufacturing organization will gain access to "new avenues of drug discovery."
ChemDiv is providing Janssen Research & Development with access to its small molecule discovery platform resources as part of a hit identification collaboration.
EAG Laboratories has added dermal absorption studies to its GLP-compliant testing services suite, as part of the company’s plan to continue expanding its capabilities.
Evotec AG and MaRS Innovation have launched Fibrocor Therapeutics LP – a new company which will focus on developing first-in-class therapeutics targeting fibrotic diseases.
A pool of contractors will compete for task orders as part of the NIAID's preclinical drug development services contract to develop therapeutics for a range of global infectious diseases.
Helomics has signed a deal with the diagnostics firm MDNA Life Sciences Inc., to help further develop MDNA’s liquid biopsy platform and commercialize its tests for prostate cancer.
Pharmaron’s acquisition of Xceleron further supports early discovery, preclinical and clinical development with expanded radiolabeled sciences capabilities.
CSSi LifeSciences and BioMARC have announced a strategic partnership to provide 'fully cohesive product development and support' for vaccine and biologic development.
Following an €8M Series A fundraising round by Eternygen GmBh, the German CRO Evotec AG will help get the virtual biotech’s metabolic disease inhibitor programme to preclinical trials.
Sharp Edge Labs will use its propriety biosensor platform to identify lead compounds for Sumitomo Dainippon Pharma – technology that the company says will help focus discussions on outcomes rather than cost.
Absorption Systems has announced a technology licensing agreement with Pfizer Inc., in which the pharma company will use the preclinical CRO’s cell lines to test potential drug candidates.
Bruker has bolstered its molecular biologics and mass spectrometric offering through the acquisition of contract manufacturing organisation (CMO) InVivo Biotech.
Crown Bioscience will invest $1m into a new subsidiary in Louisiana state to work alongside a new research facility at the New Iberia Research Center (NIRC).
GE Healthcare hopes to increase the yield of biopharmaceuticals made using its Chinese Hamster Ovary (CHO) expression system through a partnership with synthetic biology firm Synpromics.
